PharmacyCodes



Oxaprozinum [Inn-Latin] en es it fr

Categoria

Oxaprozinum [Inn-Latin] Nombres de marca, Oxaprozinum [Inn-Latin] Analogos

Oxaprozinum [Inn-Latin] Marca los nombres de mezcla

  • No information avaliable

    • Oxaprozinum [Inn-Latin] Formula quimica

    C18H15NO3

    Oxaprozinum [Inn-Latin] RX enlace

    http://www.rxlist.com/cgi/generic/oxaproz.htm

    Oxaprozinum [Inn-Latin] FDA hoja

    Oxaprozinum_[Inn-Latin] FDA

    Oxaprozinum [Inn-Latin] MSDS (hoja de seguridad de materiales)

    Oxaprozinum_[Inn-Latin] MSDS

    Oxaprozinum [Inn-Latin] Sintesis de referencia

    No hay información disponible

    Oxaprozinum [Inn-Latin] Peso molecular

    293.317 g/mol

    Oxaprozinum [Inn-Latin] Punto de fusion

    158 - 159 oC

    Oxaprozinum [Inn-Latin] H2O Solubilidad

    Insoluble

    Oxaprozinum [Inn-Latin] Estado

    Solid

    Oxaprozinum [Inn-Latin] LogP

    4.8

    Oxaprozinum [Inn-Latin] Formas de dosificacion

    Tableta

    Oxaprozinum [Inn-Latin] Indicacion

    Se utiliza para aliviar la inflamación, hinchazón, rigidez y dolor en las articulaciones asociados con la artritis reumatoide y la osteoartritis.

    Oxaprozinum [Inn-Latin] Farmacologia

    Oxaprozina es un fármaco antiinflamatorio no esteroideo (AINE) con propiedades analgésicas y antipiréticas. Oxaprozina se utiliza para tratar la artritis reumatoide, osteoartritis, dismenorrea, y para aliviar el dolor moderado.

    Oxaprozinum [Inn-Latin] Absorcion

    Oxaprozina es del 95% absorbe por vía oral. Los alimentos pueden reducir la tasa de absorción de oxaprozina, pero el grado de absorción no se modifica. Los antiácidos no afectan significativamente el alcance y la velocidad de absorción de oxaprozina.

    Oxaprozinum [Inn-Latin] Toxicidad

    Ratón por vía oral, LD50 = 1210 mg / kg, conejo Oral: LD50 = 172 mg / kg; Oral, rata: DL50 = 4470 mg / kg

    Oxaprozinum [Inn-Latin] Informacion de Pacientes

    Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up.

    Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

    Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

    Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

    In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the ductus arteriosus.

    Oxaprozinum [Inn-Latin] Organismos afectados

    Humanos y otros mamíferos